• 제목/요약/키워드: Stable Disease

Search Result 598, Processing Time 0.1 seconds

Evaluation of response to stereotactic radiosurgery in patients with radioresistant brain metastases

  • Sayan, Mutlay;Mustafayev, Teuta Zoto;Sahin, Bilgehan;Kefelioglu, Erva Seyma Sare;Wang, Shang-Jui;Kurup, Varsha;Balmuk, Aykut;Gungor, Gorkem;Ohri, Nisha;Weiner, Joseph;Ozyar, Enis;Atalar, Banu
    • Radiation Oncology Journal
    • /
    • v.37 no.4
    • /
    • pp.265-270
    • /
    • 2019
  • Purpose: Renal cell carcinoma (RCC) and melanoma have been considered 'radioresistant' due to the fact that they do not respond to conventionally fractionated radiation therapy. Stereotactic radiosurgery (SRS) provides high-dose radiation to a defined target volume and a limited number of studies have suggested the potential effectiveness of SRS in radioresistant histologies. We sought to determine the effectiveness of SRS for the treatment of patients with radioresistant brain metastases. Materials and Methods: We performed a retrospective review of our institutional database to identify patients with RCC or melanoma brain metastases treated with SRS. Treatment response were determined in accordance with the Response Evaluation Criteria in Solid Tumors. Results: We identified 53 radioresistant brain metastases (28% RCC and 72% melanoma) treated in 18 patients. The mean target volume and coverage was 6.2 ± 9.5 mL and 95.5% ± 2.9%, respectively. The mean prescription dose was 20 ± 4.9 Gy. Forty lesions (75%) demonstrated a complete/partial response and 13 lesions (24%) with progressive/stable disease. Smaller target volume (p < 0.001), larger SRS dose (p < 0.001), and coverage (p = 0.008) were found to be positive predictors of complete response to SRS. Conclusion: SRS is an effective management option with up to 75% response rate for radioresistant brain metastases. Tumor volume and radiation dose are predictors of response and can be used to guide the decision-making for patients with radioresistant brain metastases.

Characterization of canine coronaviruses isolated from the dogs with diarrhea in Korea (설사증 이환견(犬)으로 부터 분리(分離)한 canine coronavirus의 성상(性狀)에 관한 연구(硏究))

  • Lee, Byung-hyung;Jun, Moo-hyung;Park, Jong-hyeon;Hwang, Eui-kyung;Huh, Won
    • Korean Journal of Veterinary Research
    • /
    • v.34 no.3
    • /
    • pp.517-527
    • /
    • 1994
  • An attempt was made to isolate a causative viral agents from the fecal specimens of the diseased dogs with the gastroenteritis symptoms. Two coronavirus-like agents were isolated by serial dilution end point method and plaque assay. The isolates were characterized in terms of cytopathology, antigenicity, replication, physicochemical and morphological properties. The results obtained through the experiment were as follows; 1. Among 7 fecal specimens collected from the dogs with enteric disease, 2(28.6%)coronavirus-like agents showing typical cytopathic effects of canine coronavirus were isolated, and designated as CCV D1 and CCV D2, respectively. 2. By the cross-neutralization test and indirect immunofluoresence antibody test, the isolates were antigenically indentified as the standard CCV. The viruses were replicated only in the cytoplasm of A-72 cells. 3. The isolates showed no haemagglutinating activity against the erythrocytes from 11 kinds of animals. 4. The electron microscopic observation for the isolates showed spherical and pleomorphic features, covered with club-shaped projections on the surface. The size of particles was ranged from 70 to 150nm. 5. In one-step growth curve for the isolates in A-72 cells, maximum titers of intracellular vius was $10^{4.6}$ $TCID_{50}/0.1ml$ at 46 hrs postinoculation(pi) of CCV Dl and $10^{4.4}$ $TCID_{50}/0.1ml$ at 34 hrs pi of CCV D2. The maximum titers of extracellular virus was $10^{5.5}$ $TCID_{50}/0.1ml$ at 58 hrs pi of CCV D1 and $10^{5.8}$ $TCID_{50}/0.1ml$ at 46 hrs pi of CCV D2. 6. In physicochemical property test, the isolates were very sensitive to choroform and were found to be RNA virus. The viruses was stable at pH 3.0 for 1 hr and at $22{^{\circ}C}$ for 5 hrs. However, infectivity titers reduced remarkably by treatment with $56{^{\circ}C}$ for 10min.

  • PDF

Assessment of the Relationship between Pulmonary Function Test and Dyspnea Index in Patients with Bronchial Asthma (기관지천식 환자에서 폐기능검사와 호흡곤란지수의 관련성에 관한 연구)

  • Kim, Se-Kyu;Cheon, Seon-Hee;Chang, Joon;Ha, Jong-Won;Hong, Chein-Soo;Kim, Sung-Kyu;Lee, Won-Young
    • Tuberculosis and Respiratory Diseases
    • /
    • v.39 no.5
    • /
    • pp.392-399
    • /
    • 1992
  • Background: Despite dyspnea is a predominant complaint of patients with respiratory disease, the mechanisms contributing to the sensation of breathlessness are poorly understood. Traditionally, physicians have measured objective pulmonary function to assess severity of dyspnea. But it will be also useful to measure subjective dyspnea index because dyspnea probably depends on a complex interplay of mechanical, experimental, emotional and other factors. Method: We measured breathlessness at rest, after Methacholine challenge and then bronchodilator inhalation using a Visual Analogue Scale (VAS) and Borg Scale Dyspnea Index (BSDI) in stable asthmatic patients. Spirometry was performed concomittently. Results: There was no correlation between dyspnea index and FEV1. There was also no correlation between the change in dyspnea index and change in FEV1. The change in dyspnea index after methacholine and bronchodilator was greater in clinically mild asthmatic patients than clinically severe symptomatic group. Conclusion: In asthmatic patients, there was a wide variation in sensory response for any given FEV1, and the change in perception of dyspnea was greater in those with clinically mild symptoms. The measurement of dyspnea index may yield information complementary to that obtained by spirometry.

  • PDF

Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma

  • Gwak, Ho-Shin;Yee, Gi Taek;Park, Chul-Kee;Kim, Jin Wook;Hong, Yong-Kil;Kang, Seok-Gu;Kim, Jeong Hoon;Seol, Ho Jun;Jung, Tae-Young;Chang, Jong Hee;Yoo, Heon;Hwang, Jeong-Hyun;Kim, Se-Hyuk;Park, Bong Jin;Hwang, Sun-Chul;Kim, Min Su;Kim, Seon-Hwan;Kim, Eun-Young;Kim, Ealmaan;Kim, Hae Yu;Ko, Young-Cho;Yun, Hwan Jung;Youn, Ji Hye;Kim, Juyoung;Lee, Byeongil;Lee, Seung Hoon
    • Journal of Korean Neurosurgical Society
    • /
    • v.54 no.6
    • /
    • pp.489-495
    • /
    • 2013
  • Objective : To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). Methods : A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 $mg/m^2/day$) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed. Results : TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (${\geq}$grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p<0.05). Overall survival (OS) was apparently differed by the patient's histology, as AOA patients survived a median OS of 18.0 months while AO patients did not reach median OS at median follow-up of 11.5 months (range 2.7-65 months). Good performance status of Eastern Cooperative Oncology Group 0 and 1 showed prolonged OS (p<0.01). Conclusion : For recurrent AO/AOA after surgery followed by radiation therapy, TMZ could be recommended as a salvage therapy at the estimated efficacy equal to procarbazine, lomustine, and vincristine (PCV) chemotherapy at first relapse. For patients previously treated with PCV, TMZ is a favorable therapeutic option as 2nd line salvage chemotherapy with an acceptable toxicity rate.

The Effects of Visual acuity increase in mono vision by the P-VEP study using Netspeg lens (Netspag Lens를 이용한 Mono vision에서 시력개선 효과에 대한 P-VEP 연구)

  • Kim, Douk-Hoon;Bae, Han-Young;Kim, Sun-Tae
    • Journal of Korean Ophthalmic Optics Society
    • /
    • v.10 no.3
    • /
    • pp.241-246
    • /
    • 2005
  • The aim of the study was performed the wave analysis of P-VEP on the development of visual function using Netspeg lens in monocular of refraction error subjects. The P-VEP of three channels were recorded by the Bausch Lomb system. Ten adults (five males, five females, mean=22 years, range=19 to 23) subjects were recorded. The subjects were researched the history including the systemic health, medication, genetics, allergy, ocular disease, and so on. Visual acuity and refraction test were performed for each subject with mono vision by using the Netspeg lens. Also subjects viewed the P-VEP stimulus with mono vision through the corrected visual acuity with Netspeg lens during VEP test. The results of study suggest that the mono vision using Netspeg lens is better than with non-Netspeg lens on the visual acuity and image symptom. On the other hand, the analysis of P-VEP suggest that the amplitude of wave is larger when the eye using Netspeg lens receives the P-VEP stimulus compared with the non Netspeg lens. Also, on the wave style of P-VEP, the eye of Netspeg lens was more stable compared with the naked eye. However, on latency period of P-VEP, the eye of non Netspeg lens was more longer than the eye of Netspeg lens. But, on the other hand, the right and left eye have similar results. In conclusion, this study indicated that the visual acuity and visual function of eye of Netspeg lens used have a better than the eye of non-Netspeg lens in Mono Vision.

  • PDF

The Ability of Auditory Stimuli to Mask Siren Sounds in a Vehicle Graphic Simulator (자동차 그래픽 시뮬레이터에서 사이렌 소리 자극에 따른 청각 자극의 마스킹 효과)

  • Park, Jung-Sun;Kim, Gyu-Beom;Jo, Hyeong-Seok;Kim, Gyeong-Rae;Kim, Jun-Hyeong;Min, Byeong-Chan
    • Science of Emotion and Sensibility
    • /
    • v.22 no.3
    • /
    • pp.47-54
    • /
    • 2019
  • We examined previous studies of the correlation analysis of heart rate variability as a method to reduce the stress caused by outside noise during driving, and we investigated whether there are electrocardiographic changes when drivers play music, which provides a stable sound source amid the noise. Because the number of cars increases every year, drivers and passengers show an increase in stress caused by outside noise. The stress from outside noise while a person is driving can cause several disorders, such as anxiety, immunosuppression, depression, and heart disease. Subjects in this study operated a vehicle simulator to reduce the stress from outside noise and were given different auditory stimuli, and we studied the drivers' responses to the stimuli. Repeated-measures analysis of variance revealed a significant differences between subjects exposed to different auditory stimuli (ρ < 0.05). Through post hoc analyses, we examined these differences. We found significant differences between factor 1 (stability) and factor 2 (simulation driving), between factor 1 (stability) and factor 3 (driving + police siren), and between factor 1 (stability) and factor 4 (driving + police siren + music). In addition, the factor that produced the highest level of sympathetic nervous system activity was factor 4 (driving + police siren + music), followed by factor 3 (driving + police siren), factor 2 (driving), and factor 1 (stability). In conclusion, even when a police siren was heard during driving, there were no significant differences on electrocardiograms (ECGs). In addition, even when the siren was heard over the music, there was no difference on the ECGs (ρ < 0.01). In future studies, investigators should determine which types of music help stabilize the heart rate during driving.

A Case of Patient with Non-Small Cell Lung Carcinoma Treated with Samchilchoongcho-Jung in Conjunction with Crizotinib (비소세포성 폐암환자의 Crizotinib과 삼칠충초정 병용투여 경과관찰 1례)

  • Ha, Su jeong;Song, Si yeon;Park, So-jung;Jeon, Hyung-joon;Lee, Yeon-weol;Cho, Chong-kwan;Yoo, Hwa-seung
    • Journal of Korean Traditional Oncology
    • /
    • v.23 no.1
    • /
    • pp.23-32
    • /
    • 2018
  • Objective: The purpose of this study is to report the case of a patient with non-small cell lung adenocarcinoma (NSCLC) with anaplastic lymphoma kinase (ALK) mutation treated by Samchilchoongcho-Jung in conjunction with Crizotinib. Methods: An NSCLC patient diagnosed with multiple pleural and lymph nodes metastasis has been taking Crizotinib (500 mg/day) since January 2014. The patient has been treated with Samchilchoongcho-Jung (1,500 mg/day) since June 2014. The tumor size was measured by computed tomography (CT) and laboratory analysis was conducted. Adverse events were evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Results: After combining treatment, stable disease was shown on CT. The tumor marker (CEA, Cyfra 21-1) levels were maintained. NCI-CTCAE 5.0 showed no adverse events. Conclusion: This case study suggests that Samchilchoongcho-Jung may contribute to tumor response, in conjunction with Crizotinib on the treatment of patients with NSCLC.

Body Temperature Monitoring Using Subcutaneously Implanted Thermo-loggers from Holstein Steers

  • Lee, Y.;Bok, J.D.;Lee, H.J.;Lee, H.G.;Kim, D.;Lee, I.;Kang, S.K.;Choi, Y.J.
    • Asian-Australasian Journal of Animal Sciences
    • /
    • v.29 no.2
    • /
    • pp.299-306
    • /
    • 2016
  • Body temperature (BT) monitoring in cattle could be used to early detect fever from infectious disease or physiological events. Various ways to measure BT have been applied at different locations on cattle including rectum, reticulum, milk, subcutis and ear canal. In other to evaluate the temperature stability and reliability of subcutaneous temperature (ST) in highly fluctuating field conditions for continuous BT monitoring, long term ST profiles were collected and analyzed from cattle in autumn/winter and summer season by surgically implanted thermo-logger devices. Purposes of this study were to assess ST in the field condition as a reference BT and to determine any location effect of implantation on ST profile. In results, ST profile in cattle showed a clear circadian rhythm with daily lowest at 05:00 to 07:00 AM and highest around midnight and rather stable temperature readings (mean${\pm}$standard deviation [SD], $37.1^{\circ}C$ to $37.36^{\circ}C{\pm}0.91^{\circ}C$ to $1.02^{\circ}C$). STs are $1.39^{\circ}C$ to $1.65^{\circ}C$ lower than the rectal temperature and sometimes showed an irregular temperature drop below the normal physiologic one: 19.4% or 36.4% of 54,192 readings were below $36.5^{\circ}C$ or $37^{\circ}C$, respectively. Thus, for BT monitoring purposes in a fever-alarming-system, a correction algorithm is necessary to remove the influences of ambient temperature and animal resting behavior especially in winter time. One way to do this is simply discard outlier readings below $36.5^{\circ}C$ or $37^{\circ}C$ resulting in a much improved mean${\pm}$SD of $37.6^{\circ}C{\pm}0.64^{\circ}C$ or $37.8^{\circ}C{\pm}0.55^{\circ}C$, respectively. For location the upper scapula region seems the most reliable and convenient site for implantation of a thermo-sensor tag in terms of relatively low influence by ambient temperature and easy insertion compared to lower scapula or lateral neck.

Lack of Prognostic Value of Mean Corpuscular Volume with Capecitabine Therapy in Metastatic Breast Cancer

  • Bozkurt, Oktay;Berk, Veli;Kaplan, Muhammed Ali;Cetin, Bulent;Ozaslan, Ersin;Karaca, Halit;Inanc, Mevlude;Duran, Ayse Ocak;Ozkan, Metin
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.6
    • /
    • pp.2501-2504
    • /
    • 2014
  • Background: Capecitabine is an oral fluoropyrimidine derivative which is frequently used alone or in combination regimens for the treatment of metastatic breast cancer. Although overall and progression free survivals have increased in recent years with the use of new generation drugs, predictive factors that would further improve the outcomes are needed. Previous studies have demonstrated the relation between post-treatment increase in mean corpuscular volume (MCV) and predicting therapy response as well as survival. The present study investigated the clinical impact of MCV elevation in metastatic breast cancer patients treated with capecitabine. Materials and Methods: The data of a total of 82 patients from three centers followed between June 2005 and June 2013 were retrospectively analyzed. The demographic data and hormone receptor status of the patients, as well as initial examination before and after treatment and data concerning progression were recorded. MCV ${\geq}100$ fl was considered as macrocytosis. Capecitabine was given at a dose of $2500mg/m^2$ daily for 14 days every three weeks. Pre-treatment and post-treatment MCV and other parameters of complete blood count were recorded. Post-treatment initial evaluation was performed after 2 cycles of therapy. Results: The median age of the patients was 46.5 years (range 26-72 years) and 54% were premenopausal. Performance status was ECOG 0 and 1 in 81 (99%) patients. The median number of cycles for capecitabine therapy was 5 (min-max: 2-18). The median ${\Delta}MCV$ level (post-treatment values at sixth week - baseline) was 6.4. Whilst ${\Delta}MCV$ was ${\geq}6.4$ in 42 patients, it was <6.4 in 40 patients. Clinical benefit (complete response+partial response+stable disease) was observed in 37 (88%) of 42 patients with a median ${\Delta}MCV$ ${\geq}6.4$ and in 30 (75%) of 40 patients with ${\Delta}MCV$ <6.4 with no statistically significant difference (p=0.158). No significant difference was determined between the group with ${\Delta}MCV$ ${\geq}6.4$ and the group with ${\Delta}MCV$ <6.4 in terms of progression-free survival (11 vs 12 months) (p=0.55) and overall survival (20 months vs. 24 months) (p=0.11). Conclusions: The identification of new predictive markers in metastatic breast cancer is very important. In some recent studies, increase in MCV has been suggested as a marker in tumor response. In the present study, however, no significant difference was determined between tumor response and increase in MCV. Further studies including higher numbers of patients are needed to determine whether increase in MCV is a predictive marker or not.

Comparison of Efficacy and Toxicity of First Line Chemotherapy with or without Epirubicin for Patients with Advanced Stage Soft Tissue Sarcoma

  • Cao, Jie;Huang, Xin-En;Liu, Jin;Wu, Xue-Yan;Lu, Yan-Yan
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.14 no.12
    • /
    • pp.7171-7177
    • /
    • 2013
  • Purpose: To compare the safety and efficacy of first-line chemotherapy regimen with or without doxorubicin in treating patients with advanced soft tissue sarcoma (STS). Patients and Methods: We retrospectively analyzed a cohort of 56 patients histologically confirmed with STS who were treated at Jiangsu Cancer Hospital and Research Institute from July 2011 to June 2012.The basic element of first line chemotherapy contained epirubicin in group B and lacked epirubicin in group A. Response was assessed using RECIST criteria. The Kaplan-Meier method was used to estimate progress free survival (PFS). Results: According to RECIST criteria, patients in group treated by chemotherapy without epirubicin, the objective response (OR) ratio was 6.5 % (CR0%+PR6.5%). Disease control rate (DCR=CR+PR+SD) was 25.8% with a median follow-up of 14.6 months, including 2 patients achieving a partial response (PR 6.5%) and a stable response (SD 19.4%) in 6. In group B with epirubicin based regimens, no patient had complete response, PR (28 %) was observed in 7 and SD (24 %) in 6. DCR was observed in 13 patients (52%). By Fisher's exact test, the DCR difference between the two groups was statistically significant (p=0.046). In group A, median PFS was 3.0 months (95%CI:2.1-3.8), compared with 4.0 months (95% CI:3.03-4.97) in group B (p=0.0397 by log-rank test). Epirubicin based chemotherapy and ECOG performance status 0-1 were identified as favorable factors for progression in our cohort of patients. Differences of nonhematologic and hematologic toxicities were not statistically significant between the two groups, and the addition of epirobicin was not associated with cardiac toxicity (p=0.446). Conclusion: Our study demonstrates that epirubicin-based chemotherapy is effective and well tolerated, and is superior to chemotherapy without epirubicin regarding efficacy. Therefore it is recommended that epirubicin-based chemotherapy should be considered as first line for patients with advanced STS.